Investigation of Transcript Variant 6 of TPD52L2 as a Prognostic and Predictive Biomarker in Basal-Like MDA-MB-231 and MDA-MB-453 Cell Lines for Breast Cancer

Figure 4

Expression profiles of tpd52l2 transcript variants. (a) Heatmap of the expression of the ten transcript variants of the tpd52l2 gene in patients from 33 cohorts of TCGA dataset (including 469 patients with primary and metastatic cancers from SKCM and 9083 patients with primary cancers from the other 32 cohorts). Cohorts were arranged by unsupervised clustering of median transcript expression. (b) Intron and exon distributions of each transcript variant of the tpd52l2 gene. Colored bars represent exons, and white-gray bars represent introns. 0/1/2 represent the intron/exon phase. (c) Comparative analysis of tpd52l2 transcript expression in patients with primary cancers from the BRCA, COAD, LUAD, BLCA, and KIRP cohorts and in patients with primary and metastatic cancers from the SKCM cohort of TCGA dataset. Blue lines are the median expression of each transcript. Red dashed lines indicate the cutoff value of one. (d) Expression of transcript variant 5 of tpd52l2 between breast cancer tissues and paired adjacent normal tissues from the BRCA cohort of TCGA dataset. , no significant difference, paired -test. (e) Expression analysis of transcript variant 6 of tpd52l2 between breast cancer tissues and paired adjacent normal tissues grouped by PAM50 in the BRCA cohort (paired -test, ). (f) Comparative analysis of the mRNA expression level of tpd52l2 and the transcript expression levels of V5 and V6 between cancer tissues in the BRCA cohort and normal breast tissues in GTEx (Mann–Whitney test, ).

(a)

(b)

(c)

(d)

(e)

(f)